Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04127110
Title	Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE)
Acronym	ALKALINE
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	European Organisation for Research and Treatment of Cancer - EORTC
Indications	lung non-small cell carcinoma
Therapies	Lorlatinib
Age Groups:	adult \| senior
Covered Countries	NOR \| NLD \| GBR \| FRA \| ESP \| BEL